These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31598611)

  • 1. A chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform.
    Park S; Hwang SY; Shin J; Jo H; Na Y; Kwon Y
    Chem Commun (Camb); 2019 Nov; 55(85):12857-12860. PubMed ID: 31598611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
    Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
    Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism.
    Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N
    Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
    Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
    Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor.
    Jun KY; Kwon H; Park SE; Lee E; Karki R; Thapa P; Lee JH; Lee ES; Kwon Y
    Eur J Med Chem; 2014 Jun; 80():428-38. PubMed ID: 24796883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
    Bau JT; Kang Z; Austin CA; Kurz EU
    Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
    Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
    Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
    Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide quinone is a covalent poison of human topoisomerase IIβ.
    Smith NA; Byl JA; Mercer SL; Deweese JE; Osheroff N
    Biochemistry; 2014 May; 53(19):3229-36. PubMed ID: 24766193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
    Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
    Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
    Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
    Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-throughput-compatible, fluorescence anisotropy-based assay for ATP-dependent supercoiled DNA relaxation by human topoisomerase IIα.
    Shapiro AB
    Biochem Pharmacol; 2013 May; 85(9):1269-77. PubMed ID: 23415903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.
    Bergant K; Janežič M; Valjavec K; Sosič I; Pajk S; Štampar M; Žegura B; Gobec S; Filipič M; Perdih A
    Eur J Med Chem; 2019 Aug; 175():330-348. PubMed ID: 31096154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches.
    Hu W; Huang XS; Wu JF; Yang L; Zheng YT; Shen YM; Li ZY; Li X
    J Med Chem; 2018 Oct; 61(20):8947-8980. PubMed ID: 29870668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
    Ortega JA; Riccardi L; Minniti E; Borgogno M; Arencibia JM; Greco ML; Minarini A; Sissi C; De Vivo M
    J Med Chem; 2018 Feb; 61(3):1375-1379. PubMed ID: 29077404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
    Bergant K; Janezic M; Perdih A
    Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.